Retatrutide (GLP-3) Side Effects: What Phase 3 Trial Data Actually Shows

Direct Answer

Based on Phase 3 TRIUMPH trial data, retatrutide's most common side effects are gastrointestinal, consistent with the broader GLP-1 medication class: nausea (up to 42.4% at the highest 12mg dose), diarrhea (up to 32.0%), constipation (up to 26.1%), and vomiting (up to 25.3%). Retatrutide remains investigational and not FDA-approved, all of this data comes from clinical trials, not real-world prescribing.

The Distinctive Signal Worth Knowing About

Retatrutide's trials identified a dose-dependent dysesthesia signal, an abnormal skin sensation described as tingling or prickling, occurring in roughly 12.5% to 20.9% of participants at the highest dose across different Phase 3 trials. This is a genuinely distinctive finding, this specific effect has not been reported with semaglutide or tirzepatide, making it worth knowing about specifically if you're tracking retatrutide, not just assuming it shares an identical side effect profile with other GLP-1 medications.

How Severity and Discontinuation Break Down

Discontinuation due to adverse events rose with dose: 4.1% at the 4mg dose, 6.9% at 9mg, and 11.3% at 12mg, compared to a 4.9% placebo discontinuation rate. Notably, the lowest dose actually showed a lower discontinuation rate than placebo, while still producing meaningful average weight loss (19.0% at 80 weeks), a real, favorable tolerability signal at the lower end of dosing specifically. Most side effects, including the dysesthesia signal, were reported as mild to moderate and often resolved during continued treatment.

Why Trial Numbers Vary Slightly Between Reports

You may see somewhat different percentages depending on which specific TRIUMPH trial is being cited, TRIUMPH-1 and TRIUMPH-4 enrolled different patient populations and reported at different doses and durations, so minor variation between reported figures reflects genuinely different trial data, not inconsistent reporting.

What Isn't Known Yet

Long-term data beyond roughly 72 to 80 weeks is still being collected. Longer-term areas still under active study include bone density effects, lean mass loss (a consideration across the entire GLP-1 class, not unique to retatrutide), and gallbladder-related risk. TRIUMPH-5 is specifically designed to gather longer-term cardiovascular, renal, and safety data over a multi-year period.

Bottom Line

Retatrutide's side effect profile follows the same general GI pattern as other GLP-1 medications, but with one genuinely distinctive addition, dose-dependent dysesthesia, worth knowing specifically if you're tracking this medication, since it's not something you'd necessarily expect based on experience with semaglutide or tirzepatide alone.

References

• Eli Lilly and Company: TRIUMPH-1 Phase 3 Topline Results (June 2026)
• AJMC: Retatrutide Achieves Up to 30.3% Average Weight Loss in Phase 3 TRIUMPH-1 Trial
• Pharmacy Times: Retatrutide Delivers Bariatric-Level Weight Loss in Pivotal Phase 3 TRIUMPH-1 Trial
• The Pharmaceutical Journal: Phase III Retatrutide Study Demonstrates 30% Weight Loss (May 2026)

Related Resources

• Retatrutide (GLP-3) Dosing: What the Phase 3 Trials Actually Show
• Retatrutide Medication Guide
• The TRIUMPH Trials: Retatrutide's Investigational Evidence
• Is Retatrutide FDA-Approved Yet? Current Status
• What Is "GLP-3"? The Truth Behind This Trending Term

Explore More

Explore the full GLP-1 Tracker knowledge base on DietApp.com

Get Started

Track retatrutide alongside every other GLP-1 medication on DietApp.com.

About DietApp.com

DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. Retatrutide is investigational and not FDA-approved. This article is for general informational purposes and is not medical advice.